Amedisys — Q3 2022 Earnings Presentation
18 slides from Amedisys's earnings presentation, Oct 26, 2022
Slide 1: Amedisys Third Quarter 2022 Earnings Call Supplemental Slides
1 Amedisys Third Quarter 2022 Earnings Call Supplemental Slides October 27th, 2022 Exhibit 99.2
Slide 2: Forward-looking statements
2 This presentation may include forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon current expectations and assumptions about our business that are subject to a variety of risks and uncertainties that could c
Slide 3: Our Key Areas of Focus
3 Our Key Areas of Focus Strategic areas of focus and progress made during Q3’22 • Home Health*: Total same store admissions +5% • Hospice: Total same store admissions -3%, ADC +1%; +0.5% sequentially • Personal Care: PC Network drove ~$449K in revenue to Home Health and Hospice via care coordinatio
Slide 4: Highlights and Summary Financial Results (Adjusted): 3Q22
4 Highlights and Summary Financial Results (Adjusted): 3Q 2022(1) Home Health total same store admissions +5%; Hospice same store admissions -3%; EBITDA margin decline driven by the addition of Contessa (closed 8/1/2021; additional $5M in losses over Q3’21), the return of sequestration (Q3’21 benefi
Slide 5: Revenue mix and reimbursement by payor
5 66.0% 12.1% 21.6% 0.3% Home Health Revenue Medicare FFS Private Episodic Per Visit Case Rate 60.5% 35.5% 3.0% 1.0% Amedisys Consolidated Revenue Home Health Hospice Personal Care High Acuity Care • Medicare FFS: Reimbursed for a 30-day period of care • Private Episodic: MA and Commercial plans who
Slide 6: Home Health and Hospice Segment (Adjusted) – 3Q 2022
6 Home Health and Hospice Segment (Adjusted) – 3Q 2022(1) • Revenue per Episode up 0.7% (primarily due to +3.2% rate increase partially offset by the reinstatement of sequestration at 2%) • Y/Y Total CPV up $7.93 (+7.7%, primarily due to planned wage increases, wage inflation, an increase in salarie
Slide 7: General & Administrative Expenses – Adjusted
7 $ in Millions 3Q21 4Q21 1Q22 2Q22 3Q22 Home Health Segment - Total 82.4 84.7 83.2 87.8 86.9 % of HH Revenue 24.3% 25.1% 24.8% 25.2% 25.7% Hospice Segment - Total 49.5 54.0 51.3 50.8 48.6 % of HSP Revenue 25.1% 26.4% 26.6% 25.6% 24.4% Personal Care Segment - Total 2.6 2.4 2.2 2.3 2.3 % of PC Revenu
Slide 8: Operational Excellence: Home Health Cost Per Visit (CPV)
8 Operational Excellence: Home Health Cost Per Visit (CPV)-Adjusted YOY Total CPV impacted by labor cost pressures and lower visits *Note: Direct comparison with industry competitors CPV calculation $25.00 $50.00 $75.00 $100.00 3Q21 2Q22 3Q22 Cost Per Visit (CPV) Salaries Contractors Benefits Transp
Slide 9: Driving Top Line Growth
9 Driving Top Line Growth Home Health total volume impacted by lower episodic volumes. Hospice average daily census continued to improve; however, admission growth fell short of expectations due to higher turnover of our tenured business development reps. Personal Care billable hours lagging due to
Slide 10: Industry Leading Quality Scores
10 3.00 3.50 4.00 4.50 QPC Industry Performance Amedisys QPC Industry Avg QPC Top Competitor Industry Leading Quality Scores Metric Apr 22 Release Jul 22 Release Oct 22 Preview Jan 23 Preview Quality of Patient Care 4.38 4.46 4.49 4.49 Entities at 4+ Stars 97% 99% 100% 99% Quality of Patient Care (Q
Slide 11: Hospice Quality: Moving Towards Best-in-Class
11 Hospice Quality: Amedisys Hospice Continues to Move Towards Best-in-Class Hospice Quality Notes: Included in the above analysis are only active providers.
Slide 12: Debt and Liquidity Metrics
12 Debt and Liquidity Metrics Net leverage ~1.6x 1. Net debt defined as total debt outstanding ($459.8M) less cash ($31.5M). 2. Leverage ratio (net) is defined as net debt divided by last twelve months adjusted EBITDA ($267.0M). 3. Liquidity defined as the sum of cash balance and available revolving
Slide 13: Cash Flow Statement Highlights
13 Cash Flow Statement Highlights (1) Q3 cash flow statement reflects repayment related to ZPIC audit ($34M). The second half of the COVID-19 relief payroll tax deferral ($27M) is due in December 2022. 1. Free cash flow defined as cash flow from operations less routine capital expenditures and requi
Slide 14: Income Statement Adjustments
14 Income Statement Adjustments (1) 1. The financial results for the three-month periods ended September 30, 2021, December 31, 2021, March 31, 2022, June 30, 2022 and September 30, 2022 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these n
Slide 15: 2022 Guidance
15 2022 Guidance
Slide 16: Amedisys 2022 Updated Guidance
16 Amedisys 2022 Updated Guidance Revenue, EBITDA and EPS ($M except for EPS) Guidance Post Q2 Updated Guidance Adjusted Revenue $2,290 - $2,310 $2,224 - $2,230 Adjusted EBITDA $275 - $285 $253 - $258 Adjusted EPS $5.23 - $5.45 $4.82 - $4.93 Guidance Disclaimer COVID-19 has impacted the operating me
Slide 17: Environmental, Social, Governance (E.S.G.) Considerations
17 Environmental, Social, Governance (E.S.G.) Considerations
Slide 18: Environmental, Social, Governance (E.S.G.) Considerations
18 Environmental, Social, Governance (E.S.G.) Considerations Sustainable, high-quality, patient focused, home-based care model Environmental • Amedisys is dedicated to the sustainability of our business and the communities in which we serve • Environmental health has a strong correlation with physic